ES2918249T3 - Biomarcadores inflamatorios para predecir la capacidad de respuesta al compuesto FGF-18 - Google Patents
Biomarcadores inflamatorios para predecir la capacidad de respuesta al compuesto FGF-18 Download PDFInfo
- Publication number
- ES2918249T3 ES2918249T3 ES18782012T ES18782012T ES2918249T3 ES 2918249 T3 ES2918249 T3 ES 2918249T3 ES 18782012 T ES18782012 T ES 18782012T ES 18782012 T ES18782012 T ES 18782012T ES 2918249 T3 ES2918249 T3 ES 2918249T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- fgf
- compound
- cartilage
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003977 fibroblast growth factor 18 Human genes 0.000 title claims abstract description 216
- 108090000370 fibroblast growth factor 18 Proteins 0.000 title claims abstract description 216
- 150000001875 compounds Chemical class 0.000 title claims abstract description 129
- 239000000090 biomarker Substances 0.000 title claims abstract description 79
- 230000002757 inflammatory effect Effects 0.000 title description 11
- 230000004043 responsiveness Effects 0.000 title description 4
- 238000011282 treatment Methods 0.000 claims abstract description 220
- 208000015100 cartilage disease Diseases 0.000 claims abstract description 44
- 206010061762 Chondropathy Diseases 0.000 claims abstract description 34
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 210000000845 cartilage Anatomy 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 53
- 230000035945 sensitivity Effects 0.000 claims description 45
- 201000008482 osteoarthritis Diseases 0.000 claims description 39
- 206010007710 Cartilage injury Diseases 0.000 claims description 19
- 208000013201 Stress fracture Diseases 0.000 claims description 12
- 102000037865 fusion proteins Human genes 0.000 claims description 10
- 108020001507 fusion proteins Proteins 0.000 claims description 10
- 238000001356 surgical procedure Methods 0.000 claims description 10
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 9
- 210000001188 articular cartilage Anatomy 0.000 claims description 8
- 102100032752 C-reactive protein Human genes 0.000 claims description 7
- 206010017076 Fracture Diseases 0.000 claims description 6
- 102000012422 Collagen Type I Human genes 0.000 claims description 4
- 108010022452 Collagen Type I Proteins 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 3
- 108010035532 Collagen Proteins 0.000 claims description 3
- 230000004071 biological effect Effects 0.000 claims description 3
- 229920001436 collagen Polymers 0.000 claims description 3
- 229940096422 collagen type i Drugs 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 230000004044 response Effects 0.000 abstract description 42
- 210000002700 urine Anatomy 0.000 abstract description 11
- 238000002560 therapeutic procedure Methods 0.000 abstract description 10
- 210000001179 synovial fluid Anatomy 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 210000002966 serum Anatomy 0.000 abstract description 8
- 238000003745 diagnosis Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000002203 pretreatment Methods 0.000 abstract 1
- 229950002135 sprifermin Drugs 0.000 description 39
- 239000000902 placebo Substances 0.000 description 34
- 229940068196 placebo Drugs 0.000 description 33
- 230000008859 change Effects 0.000 description 28
- 239000000523 sample Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 19
- 238000002347 injection Methods 0.000 description 18
- 239000007924 injection Substances 0.000 description 18
- 210000003127 knee Anatomy 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- 230000003442 weekly effect Effects 0.000 description 15
- 206010061218 Inflammation Diseases 0.000 description 14
- 230000004054 inflammatory process Effects 0.000 description 14
- 210000000521 femorotibial joint Anatomy 0.000 description 12
- 230000008439 repair process Effects 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000092 prognostic biomarker Substances 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 108010017322 catch-relaxing peptide (Mytilus) Proteins 0.000 description 9
- 239000012472 biological sample Substances 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 238000002595 magnetic resonance imaging Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000003150 biochemical marker Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 5
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 5
- 238000000540 analysis of variance Methods 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 239000003708 ampul Substances 0.000 description 4
- 230000009266 disease activity Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- 229940124638 COX inhibitor Drugs 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 210000000968 fibrocartilage Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000003116 impacting effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101001034207 Homo sapiens Mitochondrial folate transporter/carrier Proteins 0.000 description 2
- 101000823778 Homo sapiens Y-box-binding protein 2 Proteins 0.000 description 2
- 102100039811 Mitochondrial folate transporter/carrier Human genes 0.000 description 2
- 206010065159 Polychondritis Diseases 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 230000022159 cartilage development Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- -1 sprifermin) Chemical class 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000008409 synovial inflammation Effects 0.000 description 2
- 229960003989 tocilizumab Drugs 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010011219 Costochondritis Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102100035308 Fibroblast growth factor 17 Human genes 0.000 description 1
- 108050002074 Fibroblast growth factor 17 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000032984 Intraoperative Complications Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010073853 Osteochondral fracture Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000026317 Tietze syndrome Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 206010071578 autoimmune retinopathy Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000002849 chondrocalcinosis Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000008429 joint-tissue turnover Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000009169 relapsing polychondritis Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17194169 | 2017-09-29 | ||
| EP18169317 | 2018-04-25 | ||
| PCT/EP2018/076391 WO2019063756A1 (en) | 2017-09-29 | 2018-09-28 | INFLAMMATORY BIOMARKERS FOR PREDICTING REACTIVITY TO FGF-18 COMPOUND |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2918249T3 true ES2918249T3 (es) | 2022-07-14 |
Family
ID=63722379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18782012T Active ES2918249T3 (es) | 2017-09-29 | 2018-09-28 | Biomarcadores inflamatorios para predecir la capacidad de respuesta al compuesto FGF-18 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11467169B2 (https=) |
| EP (1) | EP3688468B1 (https=) |
| JP (1) | JP7418324B2 (https=) |
| CN (1) | CN111164429B (https=) |
| AU (1) | AU2018343980B2 (https=) |
| CA (1) | CA3075713A1 (https=) |
| DK (1) | DK3688468T3 (https=) |
| ES (1) | ES2918249T3 (https=) |
| HR (1) | HRP20220737T1 (https=) |
| HU (1) | HUE058848T2 (https=) |
| IL (1) | IL273574B2 (https=) |
| LT (1) | LT3688468T (https=) |
| PL (1) | PL3688468T3 (https=) |
| RS (1) | RS63292B1 (https=) |
| SI (1) | SI3688468T1 (https=) |
| WO (1) | WO2019063756A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016211950A1 (en) | 2015-01-29 | 2017-07-13 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| IL273613B2 (en) | 2017-09-29 | 2026-02-01 | Merck Patent Gmbh | Metabolic biomarkers for predicting response to FGF-18 compound |
| SI3688468T1 (sl) | 2017-09-29 | 2022-08-31 | Merck Patent Gmbh | Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18 |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2339002A1 (en) | 1996-10-16 | 2011-06-29 | ZymoGenetics, Inc. | Fibroblast growth factor homologs |
| ES2493840T3 (es) | 2002-10-07 | 2014-09-12 | Zymogenetics, Inc. | Procedimiento de administración de FGF-18 |
| AU2003287697A1 (en) | 2002-11-08 | 2004-06-03 | Barnes-Jewish Hospital | Uncoupled collagen synthesis and degradation assays |
| AU2005314438B2 (en) | 2004-12-10 | 2012-03-29 | Zymogenetics, Inc. | FGF18 production in prokaryotic hosts |
| US8224579B2 (en) | 2005-06-17 | 2012-07-17 | The Brigham And Women's Hospital, Inc. | Method of diagnosing osteoarthritis |
| HRP20120643T1 (hr) | 2006-08-25 | 2012-08-31 | Ares Trading S.A. | Liječenje poremećaja hrskavice sa fgf-18 |
| JP2009257842A (ja) | 2008-04-14 | 2009-11-05 | Ttc:Kk | 変形性関節症の検査方法及び診断用キット |
| JP5762282B2 (ja) | 2008-05-02 | 2015-08-12 | インタールーキン ジェネティクス， インコーポレイテッド | 変形性関節症に関連する状態に対する遺伝的素因の検出 |
| US20090299769A1 (en) | 2008-05-29 | 2009-12-03 | Nordic Bioscience Imaging A/S | Prognostic osteoarthritis biomarkers |
| US20120115137A1 (en) | 2010-08-31 | 2012-05-10 | Kornman Kenneth S | Methods of Predicting Osteoarthritis |
| TWI527590B (zh) | 2011-06-17 | 2016-04-01 | 艾瑞斯貿易公司 | Ｆｇｆ－１８之凍乾調配物 |
| AU2013301607B2 (en) | 2012-08-06 | 2018-10-18 | Merck Patent Gmbh | Prognosis biomarkers in cartilage disorders |
| CN104736723B (zh) * | 2012-08-06 | 2017-10-31 | 默克专利有限公司 | 用于预测对fgf‑18化合物的响应性的遗传标记 |
| CA2931978A1 (en) * | 2013-12-02 | 2015-06-11 | Abbvie Inc. | Compositions and methods for treating osteoarthritis |
| KR102622290B1 (ko) | 2013-12-24 | 2024-01-05 | 아레스 트레이딩 에스.아. | 크실로글루칸 겔 중의 fgf-18 제형물 |
| ES2806026T3 (es) | 2013-12-24 | 2021-02-16 | Ares Trading Sa | Formulación de FGF-18 en hidrogeles de alginato/colágeno |
| HUE040350T2 (hu) * | 2014-02-20 | 2019-03-28 | Merck Patent Gmbh | FGF-18 vegyületadagoló étrend |
| MX2016010873A (es) | 2014-02-20 | 2016-11-17 | Merck Patent Gmbh | Factor de crecimiento de fibroblastos 18 en los procedimientos para el trasplante de injertos y para ingenieria de tejidos. |
| JP6510547B2 (ja) | 2014-02-20 | 2019-05-08 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｆｇｆ−１８を含むインプラント |
| AU2016211950A1 (en) | 2015-01-29 | 2017-07-13 | Ares Trading S.A. | Immunoassays for high positively charged proteins |
| MX380092B (es) | 2015-11-06 | 2025-03-11 | Samumed Llc | Tratamiento de la osteoartritis. |
| US9983214B2 (en) | 2016-04-15 | 2018-05-29 | Esm Technologies, Llc | Method for evaluating articular joint therapeutics |
| SI3688468T1 (sl) | 2017-09-29 | 2022-08-31 | Merck Patent Gmbh | Vnetni biomarkerji za predvidevanje odzivov na spojino FGF-18 |
| IL273613B2 (en) | 2017-09-29 | 2026-02-01 | Merck Patent Gmbh | Metabolic biomarkers for predicting response to FGF-18 compound |
| IL281333B2 (en) | 2018-09-10 | 2025-11-01 | Merck Patent Gmbh | A method for reducing risk in a clinical trial |
-
2018
- 2018-09-28 SI SI201830693T patent/SI3688468T1/sl unknown
- 2018-09-28 WO PCT/EP2018/076391 patent/WO2019063756A1/en not_active Ceased
- 2018-09-28 US US16/650,878 patent/US11467169B2/en active Active
- 2018-09-28 LT LTEPPCT/EP2018/076391T patent/LT3688468T/lt unknown
- 2018-09-28 CN CN201880063173.4A patent/CN111164429B/zh active Active
- 2018-09-28 HU HUE18782012A patent/HUE058848T2/hu unknown
- 2018-09-28 AU AU2018343980A patent/AU2018343980B2/en active Active
- 2018-09-28 IL IL273574A patent/IL273574B2/en unknown
- 2018-09-28 ES ES18782012T patent/ES2918249T3/es active Active
- 2018-09-28 JP JP2020517797A patent/JP7418324B2/ja active Active
- 2018-09-28 CA CA3075713A patent/CA3075713A1/en active Pending
- 2018-09-28 EP EP18782012.1A patent/EP3688468B1/en active Active
- 2018-09-28 HR HRP20220737TT patent/HRP20220737T1/hr unknown
- 2018-09-28 RS RS20220541A patent/RS63292B1/sr unknown
- 2018-09-28 DK DK18782012.1T patent/DK3688468T3/da active
- 2018-09-28 PL PL18782012.1T patent/PL3688468T3/pl unknown
-
2022
- 2022-09-01 US US17/929,261 patent/US12332250B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RS63292B1 (sr) | 2022-06-30 |
| HRP20220737T1 (hr) | 2022-09-02 |
| IL273574B1 (en) | 2024-09-01 |
| AU2018343980A1 (en) | 2020-04-02 |
| CN111164429B (zh) | 2024-08-09 |
| AU2018343980B2 (en) | 2025-04-10 |
| EP3688468B1 (en) | 2022-03-16 |
| LT3688468T (lt) | 2022-06-27 |
| US12332250B2 (en) | 2025-06-17 |
| US20230258659A1 (en) | 2023-08-17 |
| PL3688468T3 (pl) | 2022-07-18 |
| US11467169B2 (en) | 2022-10-11 |
| IL273574B2 (en) | 2025-01-01 |
| SI3688468T1 (sl) | 2022-08-31 |
| WO2019063756A1 (en) | 2019-04-04 |
| IL273574A (en) | 2020-05-31 |
| CA3075713A1 (en) | 2019-04-04 |
| JP7418324B2 (ja) | 2024-01-19 |
| EP3688468A1 (en) | 2020-08-05 |
| CN111164429A (zh) | 2020-05-15 |
| DK3688468T3 (da) | 2022-06-20 |
| JP2020535423A (ja) | 2020-12-03 |
| HUE058848T2 (hu) | 2022-09-28 |
| US20210231680A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2980597T3 (es) | Marcadores útiles en las estrategias de enriquecimiento para el tratamiento de la artrosis | |
| US12332250B2 (en) | Inflammatory biomarkers for predicting responsiveness to FGF-18 compound | |
| US12332251B2 (en) | Metabolic biomarkers for predicting responsiveness to FGF-18 compound | |
| HK40058829B (en) | Markers useful in enrichment strategies for the treatment of osteoarthritis | |
| HK40058829A (en) | Markers useful in enrichment strategies for the treatment of osteoarthritis |